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We investigated the potential correlation between the character-
istics prior transplantation and the subsequent clinical outcomes in
175 consecutive patients who received HSC transplantation from
HLA-mismatched/haploidentical donors. Patients eligible for
study were those with a diagnosis of leukemia, all lacking an HLA
matched sibling or unrelated donor. Patients ranged in age from 6
to 53 years (median 25 years) and donors from 13 to 66 years
(median 40 years). Compatibility testing of family members in-
cluded serology and intermediate resolution DNA typing for
HLA-A, -B, and -C antigens, plus high resolution DNA typing for
HLA-DRB1, -DQB1, and -DPB1. Donors included 72 mothers
(41%), 29 fathers (16.6%), 54 siblings (31%), 16 children (9%), 4
cousins (2.3%), with various grades of HLA disparity: 28 (16%)
with 1; 79 (45%) with 2; 68 (39%) with 3 antigen mismatch. Grafts
(BMPB) was harvested from donor BM collected after four days
of G-CSF, and PB collected after 5 days of G-CSF. The graft was
analyzed for content of CD34 cells and subsets of lymphoid cell
populations, CD3, CD4, CD8, and CD14, using standard-
ized Multi-set kits (Becton-Dickinson, San Jose, CA, USA). All
patients enrolled in this study were treated with a uniform condi-
tioning regimen (BuCy2ATG), given GVHD prophylaxis
(CsA short term MTX), and followed from 36 to 1191days after
transplantation (median 401 days). Univariate analysis for survival
indicated that disease status prior transplantation and donor CD3
cell dose were the only predictors of the 2-year probability of
survival: early disease (77.8%), intermediate disease (38%), and
those with advanced disease (52%), [P0.018]; survival in those
given a CD3 cell dose 150 106/kg was 52% and CD3 cell
dose 150106/kg was 74%, respectively [P0.0215]. This was
conﬁrmed by multivariate analysis: patients transplanted with in-
termediate/advanced stage disease [RR1.568 (95% CI, 1.128-
2.17); P0.007] had a worse overall survival; Infusion of a high
dose of CD3 cells (150  106/kg) had improved survival [0.530
(0.300-0.95); P0.03] without increase the incidence of developing
Grade 3-4 aGVHD [1.27 (0.58-2.76); P0.56]. Our data have
indicated that with the current protocol, patients given a relatively
high dose of CD3 cells (150106/kg) have a signiﬁcantly better
overall survival after transplantation than those given lower doses
of CD3 cells (150 106/kg).
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Identiﬁcation of at least one fully compatible unrelated blood
stem cell donor requires conﬁrmatory typing (CT) of 2-5 poten-
tially matched donors. We developed an algorithm, based on the
frequency of the HLA-DRB1 alleles and the estimated DRB1-
DQB1 haplotypes of the patient, which deﬁned the number of
potentially matched donors requested for CT. This strategy aimed
to result to a shorter UDS duration as well as to cost-effectiveness
in the process of a Unrelated donor search (UDS).
HLA-DRB1 allele frequencies were calculated based on the Na-
tional Marrow Donor Program dataset of 65752 individuals. HLA-
DRB1-DQB1 haplotype data were obtained from the German
National Donor Registry (ZKRD). HLA-DRB1 allele frequencies
within a given broad allele family (e.g. HLA-DRB1*11) were the
main point of consideration, since for most donors only a low
resolution typing was available. HLA-DRB1 alleles with a fre-
quency of 80-100% within their broad allele family were consid-
ered as very frequent. Alleles with a frequency of 30-79% within
their broad allele family as average, and a frequency of 0-29% as
rare. In addition, if the association of a particular HLA-DRB1
allele with the corresponding HLA- DQB1 allele was more fre-
quent than 80%, this DRB1-DQB1 haplotype was considered as
very common. A haplotype corresponding to 20% to 79% of a
given DRB1 allele was classiﬁed as average, whereas a haplotype
frequency of lower than 20% of a particular DRB1 allele was
considered as rare. Based on this algorithm, the probability to ﬁnd
a fully compatible donor for a patient was considered high, me-
dium or low. For the patients with high, medium or low probabil-
ity, three, 4 or 5 potentially matched unrelated donors were re-
quested for CT at the beginning of a UDS, respectively.
In a group of 794 patients, the average duration of UDS and the
average number of identiﬁed donors has been calculated. Eighty
percent of the searches showed a high, 7% a medium and 13% a
low probability to ﬁnd a fully compatible donor. The average UDS
duration was 55, 105, and 135 days in the three groups, respec-
tively. An average of 2.0, 1.6, and 1.0 donors were found in the
groups with high, medium, and low probability, respectively.
The algorithm used in our search unit, allows a prediction of
UDS duration and the estimation of the UDS success rate. A
variable number of potentially matched donors should be re-
quested for CT, which allows economising the UDS process with-
out prolongation of the UDS duration.
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Although allogeneic stem cell transplantation from a human
leukocyte antigen (HLA)-identical related donor offers a potential
cure for patients with acute myeloid leukemia (AML) not in re-
mission, a suitably matched related donor is unavailable for ap-
proximately two-thirds of patients. Recently, umbilical cord blood
from unrelated donors have been used as an alternative stem cell
source for adult patients with AML. Here, we report our clinical
results of unrelated cord blood transplantation (CBT) after my-
eloablative conditioning for 30 adult patients with AML not in
remission. Between August 1998 and November 2005, 30 adult
patients with AML not in remission were treated with unrelated
CBT at The Institute of Medical Science, University of Tokyo.
Diagnoses at transplantation included de novo AML (n14) and
MDS-related secondary AML (n16). All patients received four
fractionated 12 Gy total body irradiation and chemotherapy as
myeloablative conditioning. 27 patients received standard cyclo-
sporine (CyA) and methotrexate, and 3 patients received CyA only
as a graft-versus-host disease (GVHD) prophylaxis. Among the
patients the median age was 45.5 years (range, 19-55 years), the
median weight was 55 kg (range, 36-76 kg) and the median number
of cryopreserved nucleated cells was 2.43  107/kg (range, 1.16-
5.29  107/kg). 28 patients had myeloid reconstitution and the
median time to more than 0.5  109/L absolute neutrophil count
was 21.5 days. A self-sustained platelet count more than 50 
109/L was achieved in 23 patients at a median time of 42 days.
Acute GVHD above grade II occurred in 15 of 28 evaluable
patients and chronic GVHD occurred in 17 of 23 evaluable pa-
tients. Among 17 chronic GVHD patients, 7 patients were exten-
sive type. 16 patients are alive and free of disease at between 280
and 2937 days after transplantation. With a median follow-up of
2013 days, the probability of disease-free survival at 5 years was
51.8%. These results suggest that adult patients with AML not in
remission should be considered as candidates for CBT.
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